Oppenheimer maintains Outperform on Amrize, lowers price target to $65

0 min read | Published on 22 Jul 2026, 02:35 AM |Updated on 22 Jul 2026, 02:35 AM

Reviewed by

Radhika SScanX News Team

Key Highlights

Oppenheimer analyst Bryan Blair maintained an Outperform rating on Amrize (NYSE: AMRZ) but lowered the price target to $65 from $68.

*this image is generated using AI for illustrative purposes only.

Oppenheimer analyst Bryan Blair has maintained an Outperform rating on Amrize (NYSE: AMRZ) while adjusting the valuation expectations for the stock. The firm lowered the price target to $65, down from the previous $68.

The revised target reflects updated analysis by the brokerage, though the underlying Outperform stance suggests continued confidence in the company's performance relative to the market. The adjustment provides a new reference point for investors tracking the stock's potential upside.

What factors drove Oppenheimer to lower the price target despite maintaining an Outperform rating?

How might this price target adjustment influence investor sentiment toward Amrize in the short term?

What upcoming catalysts could help Amrize reach the revised $65 price target?

Amrize Faces Mixed Analyst Signals: Truist Downgrades, Wells Fargo Holds Overweight

1 min read | Published on 07 Jul 2026, 04:28 PM |Updated on 08 Jul 2026, 09:52 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Amrize faces contrasting analyst actions, with Truist Securities downgrading the stock from Buy to Hold and cutting the price target to $48 from $65, while Wells Fargo's Timna Tanners retains an Overweight rating but lowers the price target from $65 to $58, signaling a cautious yet relatively constructive outlook from the latter.

*this image is generated using AI for illustrative purposes only.

Amrize is receiving divergent signals from Wall Street, as two prominent analysts revise their outlooks on the stock. Truist Securities analyst Keith Hughes has downgraded Amrize from Buy to Hold, slashing the price target to $48 from $65. Meanwhile, Wells Fargo analyst Timna Tanners maintains an Overweight rating but also trims the price target from $65 to $58, reflecting a more cautious near-term view while retaining a broadly positive stance on the stock.

Analyst Ratings and Price Target Summary

The following table outlines the latest analyst actions on Amrize:

Analyst Detail:	Truist Securities	Wells Fargo
Analyst:	Keith Hughes	Timna Tanners
Previous Rating:	Buy	Overweight
New Rating:	Hold	Overweight
Previous Price Target:	$65	$65
New Price Target:	$48	$58

Diverging Perspectives

The Truist Securities downgrade represents a more significant shift in sentiment, moving Amrize entirely out of the Buy category and signaling reduced confidence in the stock's near-term upside. The revised price target of $48 marks a substantial decline from the prior $65 target. In contrast, Wells Fargo's decision to maintain its Overweight rating suggests continued long-term conviction in the stock, even as the lowered price target of $58 acknowledges potential headwinds. Together, these actions reflect a broader recalibration of expectations around Amrize's valuation among institutional analysts.

What specific near-term headwinds prompted the significant reduction in price targets by both analysts?

How might the divergence in analyst ratings impact institutional investor sentiment toward Amrize?

What factors could drive Wells Fargo to maintain its Overweight rating despite lowering its price target?